New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!
Daniel  Bradbury net worth and biography

Daniel Bradbury Biography and Net Worth

Director of Castle Biosciences
Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Since June 2018, Mr. Bradbury has served as Chief Executive Officer of Equillium, Inc., a publicly traded biotechnology company, where he also served as its President from March 2017 until June 2018. Mr. Bradbury is the founder of, and has served as the managing member of, BioBrit, LLC, a life sciences consulting and investment firm, since September 2012. Mr. Bradbury served as President, Chief Executive Officer and a director of Amylin Pharmaceuticals, Inc. from March 2007 until Amylin’s acquisition by Bristol-Myers Squibb Company in August 2012. Prior to Amylin, Mr. Bradbury worked in marketing and sales for ten years at SmithKline Beecham Pharmaceuticals. Mr. Bradbury serves on the board of directors of numerous private companies and two publicly traded companies, Equillium, Inc. and Intercept Pharmaceuticals, Inc. He previously served on the board of directors of the following publicly traded companies: Corcept Therapeutics, Inc., from 2012 to 2019; Geron Corporation, from 2012 to 2019; and Illumina, Inc. from 2004 to 2017. Mr. Bradbury holds a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.

What is Daniel Bradbury's net worth?

The estimated net worth of Daniel Bradbury is at least $1.05 million as of December 4th, 2023. Mr. Bradbury owns 53,020 shares of Castle Biosciences stock worth more than $1,051,387 as of December 6th. This net worth evaluation does not reflect any other assets that Mr. Bradbury may own. Learn More about Daniel Bradbury's net worth.

How do I contact Daniel Bradbury?

The corporate mailing address for Mr. Bradbury and other Castle Biosciences executives is 820 S FRIENDSWOOD DRIVE SUITE 201, FRIENDSWOOD TX, 77546. Castle Biosciences can also be reached via phone at (866) 788-9007 and via email at [email protected]. Learn More on Daniel Bradbury's contact information.

Has Daniel Bradbury been buying or selling shares of Castle Biosciences?

During the last ninety days, Daniel Bradbury has sold $758,791.69 in Castle Biosciences stock. Most recently, Daniel Bradbury sold 4,340 shares of the business's stock in a transaction on Monday, December 4th. The shares were sold at an average price of $20.08, for a transaction totalling $87,147.20. Following the completion of the sale, the director now directly owns 53,020 shares of the company's stock, valued at $1,064,641.60. Learn More on Daniel Bradbury's trading history.

Who are Castle Biosciences' active insiders?

Castle Biosciences' insider roster includes Daniel Bradbury (Director), Jeffrey Eberwein (CEO), Tobin Juvenal (Insider), David Kabakoff (Director), Derek Maetzold (Insider), Kristen Oelschlager (COO), Bernhard Spiess (Insider), Frank Stokes (CFO), and Adam Sussman (Director). Learn More on Castle Biosciences' active insiders.

Are insiders buying or selling shares of Castle Biosciences?

During the last year, Castle Biosciences insiders bought shares 1 times. They purchased a total of 4,800 shares worth more than $69,024.00. During the last year, insiders at the sold shares 28 times. They sold a total of 188,106 shares worth more than $3,967,273.53. The most recent insider tranaction occured on December, 4th when insider Derek J Maetzold sold 1,379 shares worth more than $27,690.32. Insiders at Castle Biosciences own 7.7% of the company. Learn More about insider trades at Castle Biosciences.

Information on this page was last updated on 12/4/2023.

Daniel Bradbury Insider Trading History at Castle Biosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/4/2023Sell4,340$20.08$87,147.2053,020View SEC Filing Icon  
12/1/2023Sell9,545$20.05$191,377.2554,502View SEC Filing Icon  
11/29/2023Sell17,342$20.12$348,921.0460,197View SEC Filing Icon  
11/24/2023Sell800$20.02$16,016.0063,665View SEC Filing Icon  
11/20/2023Sell5,755$20.04$115,330.2063,885View SEC Filing Icon  
9/1/2023Sell1,802$20.04$36,112.0865,037View SEC Filing Icon  
8/30/2023Sell4,632$20.03$92,778.9666,854View SEC Filing Icon  
7/7/2023Sell50,000$20.39$1,019,500.0067,780View SEC Filing Icon  
5/4/2023Sell17,643$21.69$382,676.6779,251View SEC Filing Icon  
4/5/2023Sell7,100$22.20$157,620.0082,780View SEC Filing Icon  
4/3/2023Sell10,300$22.14$228,042.0085,720View SEC Filing Icon  
3/2/2023Sell11,349$23.30$264,431.7090,510View SEC Filing Icon  
1/3/2023Sell7,704$22.89$176,344.56199,539View SEC Filing Icon  
10/3/2022Sell7,704$27.17$209,317.68222,651View SEC Filing Icon  
8/1/2022Sell7,704$27.47$211,628.88238,059View SEC Filing Icon  
3/29/2022Sell8,852$45.32$401,172.64View SEC Filing Icon  
3/14/2022Sell8,852$38.21$338,234.92View SEC Filing Icon  
2/22/2022Sell8,852$39.02$345,405.04View SEC Filing Icon  
2/9/2022Sell8,852$46.53$411,883.56View SEC Filing Icon  
1/24/2022Sell14,631$35.42$518,230.02View SEC Filing Icon  
1/20/2022Sell15,604$35.26$550,197.04View SEC Filing Icon  
1/18/2022Sell2,470$35.30$87,191.00View SEC Filing Icon  
1/4/2022Sell16,353$43.58$712,663.74View SEC Filing Icon  
11/8/2021Sell5,554$61.21$339,960.34View SEC Filing Icon  
11/4/2021Sell4,446$61.05$271,428.30View SEC Filing Icon  
10/21/2021Sell5,000$62.94$314,700.00View SEC Filing Icon  
10/4/2021Sell5,000$60.93$304,650.00View SEC Filing Icon  
9/21/2021Sell5,000$73.95$369,750.00View SEC Filing Icon  
8/17/2021Sell644$60.02$38,652.88View SEC Filing Icon  
8/3/2021Sell5,000$69.62$348,100.00View SEC Filing Icon  
7/26/2021Sell5,000$66.78$333,900.00View SEC Filing Icon  
7/8/2021Sell5,000$69.56$347,800.00View SEC Filing Icon  
4/7/2021Sell15,000$72.81$1,092,150.00View SEC Filing Icon  
3/24/2021Sell7,500$63.09$473,175.00View SEC Filing Icon  
2/23/2021Sell7,500$79.63$597,225.00View SEC Filing Icon  
1/25/2021Sell7,500$76.94$577,050.00View SEC Filing Icon  
1/12/2021Sell12,113$78.29$948,326.77View SEC Filing Icon  
12/29/2020Sell30,000$69.69$2,090,700.00View SEC Filing Icon  
10/20/2020Sell11,750$49.70$583,975.00View SEC Filing Icon  
9/16/2020Sell3,750$48.38$181,425.00View SEC Filing Icon  
9/2/2020Sell7,500$45.66$342,450.00View SEC Filing Icon  
8/18/2020Sell3,750$43.18$161,925.00View SEC Filing Icon  
8/6/2020Sell3,750$41.34$155,025.00View SEC Filing Icon  
7/21/2020Sell3,750$41.81$156,787.50View SEC Filing Icon  
7/8/2020Sell7,500$41.08$308,100.00View SEC Filing Icon  
6/3/2020Sell3,750$37.01$138,787.50View SEC Filing Icon  
5/21/2020Sell3,750$37.21$139,537.50208,053View SEC Filing Icon  
See Full Table

Daniel Bradbury Buying and Selling Activity at Castle Biosciences

This chart shows Daniel Bradbury's buying and selling at Castle Biosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Castle Biosciences Company Overview

Castle Biosciences logo
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Read More

Today's Range

Now: $19.74
Low: $19.48
High: $20.05

50 Day Range

MA: $16.53
Low: $12.19
High: $20.06

2 Week Range

Now: $19.74
Low: $9.26
High: $29.59


82,932 shs

Average Volume

368,318 shs

Market Capitalization

$531.22 million

P/E Ratio


Dividend Yield